CY1114792T1 - Κλωστριδιακες τοξινες για χρηση στην θεραπεια προωρης εκσπερματισης - Google Patents

Κλωστριδιακες τοξινες για χρηση στην θεραπεια προωρης εκσπερματισης

Info

Publication number
CY1114792T1
CY1114792T1 CY20141100075T CY141100075T CY1114792T1 CY 1114792 T1 CY1114792 T1 CY 1114792T1 CY 20141100075 T CY20141100075 T CY 20141100075T CY 141100075 T CY141100075 T CY 141100075T CY 1114792 T1 CY1114792 T1 CY 1114792T1
Authority
CY
Cyprus
Prior art keywords
toxins
closed
effective treatment
early effective
patient
Prior art date
Application number
CY20141100075T
Other languages
English (en)
Inventor
Gustavo M Gaxiola
Ivan E Aguilar
Gilberto P Paz
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of CY1114792T1 publication Critical patent/CY1114792T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Παρουσιάζονται μέθοδοι παράτασης του χρόνου οργασμού σε έναν ασθενή που έχει ανάγκη αυτής, όπως παρέχονται μέθοδοι για θεραπεία πρόωρης εκσπερμάτισης με τοπική χορήγηση μιας Κλωστριδικακής νευροτοξίνης όπως νευροτοξίνης αλλαντοτοξίνης στον ασθενή.
CY20141100075T 2009-08-26 2014-01-29 Κλωστριδιακες τοξινες για χρηση στην θεραπεια προωρης εκσπερματισης CY1114792T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/548,073 US8147848B2 (en) 2009-08-26 2009-08-26 Method for treating premature ejaculation with a botulinum neurotoxin
EP10742993.8A EP2470202B1 (en) 2009-08-26 2010-08-10 Clostridial toxins for use in treating premature ejaculation

Publications (1)

Publication Number Publication Date
CY1114792T1 true CY1114792T1 (el) 2016-12-14

Family

ID=43127150

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100075T CY1114792T1 (el) 2009-08-26 2014-01-29 Κλωστριδιακες τοξινες για χρηση στην θεραπεια προωρης εκσπερματισης

Country Status (18)

Country Link
US (8) US8147848B2 (el)
EP (2) EP2708239B1 (el)
JP (2) JP5766699B2 (el)
KR (1) KR101612988B1 (el)
CN (2) CN103816530B (el)
AU (2) AU2010289969B2 (el)
BR (1) BR112012004246A2 (el)
CA (1) CA2772372C (el)
CY (1) CY1114792T1 (el)
DK (2) DK2470202T3 (el)
ES (2) ES2446969T3 (el)
IN (1) IN2012DN02210A (el)
MX (2) MX2012002378A (el)
PL (1) PL2470202T3 (el)
PT (1) PT2470202E (el)
RU (1) RU2568844C2 (el)
SI (1) SI2470202T1 (el)
WO (1) WO2011028371A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US20120251518A1 (en) * 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20130066148A1 (en) * 2011-09-12 2013-03-14 Kang Seon Cho Method of augmenting glans
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
US9764010B2 (en) * 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin
JP6643324B2 (ja) * 2014-09-02 2020-02-12 アメリカン シルヴァー リミテッド ライアビリティ カンパニー ボツリヌス毒素及びコロイド状銀粒子
RU2565104C1 (ru) * 2014-10-24 2015-10-20 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения преждевременной эякуляции
MX2019013716A (es) * 2017-05-18 2020-10-12 Revance Therapeutics Inc Métodos de tratamiento para la distonía cervical.
WO2018220232A1 (en) * 2017-06-02 2018-12-06 Universite De Versailles-St Quentin En Yvelines Pharmaceutical combination product comprising botulinum toxin for the treatment of erectile dysfunction
US12102556B2 (en) 2022-05-31 2024-10-01 Max Azevedo System and method for fallopian birth control
US12337014B1 (en) 2024-06-17 2025-06-24 Enrico Guarino Intracavernosal gel infusion system with neurotoxin modulation for erectile function

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5427291A (en) 1993-09-21 1995-06-27 Smith; David S. Ski carrier and method employing same
ES2332905T3 (es) 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CN1123680A (zh) * 1994-11-18 1996-06-05 吕建京 一种对于肺脾肾虚有良好功效的保健品及其制造方法
EP1011695B2 (en) 1997-07-15 2009-11-04 The Regents of the University of Colorado Use of neurotoxin therapy for treatment of prostate disorders
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
CN1146866C (zh) * 1998-11-17 2004-04-21 阿尔卑斯电气株式会社 浮起式磁头的冠顶形成方法及冠顶形成装置
FR2793689B1 (fr) 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
RU2180591C2 (ru) * 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
EP1397126B9 (en) 2001-03-16 2007-02-21 DMI Biosciences, Inc. Use of tramadol for delaying ejaculation
JP2004531506A (ja) 2001-03-29 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的なセロトニン再取り込みインヒビターとしてのシクロプロピルインドール誘導体
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
DK1474143T3 (da) * 2002-01-25 2009-01-26 Modular Properties Ltd Fremgangsmåder og sammensætninger til bahandling af mandlig erektil dysfunktion
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
TW200418838A (en) * 2002-09-18 2004-10-01 Bristol Myers Squibb Co Compounds for the treatment of premature ejaculation
US20070264373A1 (en) * 2004-01-26 2007-11-15 Ian Carroll Toxin Induced Sympathectomy
US20060100584A1 (en) 2004-08-10 2006-05-11 Orest Olejnik Needleless microprotrusion elastoplast system
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
CN1682810A (zh) * 2005-02-22 2005-10-19 黄资源 一种治疗前列腺疾病的前列外敷散
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7445783B2 (en) 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
US20090005319A1 (en) * 2007-07-01 2009-01-01 Barone Jr Frank V Topical compositions for delaying ejaculation and methods of using the same
US20090093547A1 (en) * 2007-10-09 2009-04-09 Sciele Pharma, Inc. Compositions and Methods for Treating Premature Ejaculation
EP2211890A1 (en) 2007-10-23 2010-08-04 Allergan, Inc. Methods of treating urogenital-neurological disorders using modified clostridial toxins
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US9049616B2 (en) 2012-03-29 2015-06-02 Broadcom Corporation Session recovery after network coordinator or AP restart for single user, multiple user, multiple access, and/or MIMO wireless communications
US9764010B2 (en) 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin

Also Published As

Publication number Publication date
SI2470202T1 (sl) 2014-02-28
US20120148563A1 (en) 2012-06-14
KR20120103760A (ko) 2012-09-19
US8329193B2 (en) 2012-12-11
RU2568844C2 (ru) 2015-11-20
US20160067319A1 (en) 2016-03-10
PL2470202T3 (pl) 2014-05-30
ES2446969T3 (es) 2014-03-11
EP2708239B1 (en) 2015-12-09
EP2470202B1 (en) 2013-12-18
AU2015213381A1 (en) 2015-09-03
US9907841B2 (en) 2018-03-06
DK2708239T3 (en) 2016-03-14
IN2012DN02210A (el) 2015-08-21
US20110052636A1 (en) 2011-03-03
BR112012004246A2 (pt) 2016-04-05
CA2772372A1 (en) 2011-03-10
HK1171658A1 (en) 2013-04-05
CN103816530B (zh) 2016-12-07
US20150064167A1 (en) 2015-03-05
CN102802663A (zh) 2012-11-28
EP2708239A1 (en) 2014-03-19
AU2010289969A1 (en) 2012-03-22
RU2012110324A (ru) 2013-10-10
US20130059789A1 (en) 2013-03-07
PT2470202E (pt) 2014-02-24
MX349947B (es) 2017-08-22
CA2772372C (en) 2016-07-12
ES2564677T3 (es) 2016-03-28
AU2010289969B2 (en) 2015-05-14
JP2013503165A (ja) 2013-01-31
US20140140981A1 (en) 2014-05-22
CN102802663B (zh) 2014-03-19
US9186395B2 (en) 2015-11-17
MX2012002378A (es) 2012-06-28
DK2470202T3 (da) 2014-01-27
JP2015163654A (ja) 2015-09-10
JP6078108B2 (ja) 2017-02-08
US8916177B2 (en) 2014-12-23
AU2015213381B2 (en) 2017-05-25
WO2011028371A1 (en) 2011-03-10
US10420823B2 (en) 2019-09-24
US20170020997A1 (en) 2017-01-26
US20180185460A1 (en) 2018-07-05
KR101612988B1 (ko) 2016-04-15
CN103816530A (zh) 2014-05-28
US9457069B2 (en) 2016-10-04
JP5766699B2 (ja) 2015-08-19
US8617570B2 (en) 2013-12-31
EP2470202A1 (en) 2012-07-04
US8147848B2 (en) 2012-04-03
HK1194292A1 (en) 2014-10-17

Similar Documents

Publication Publication Date Title
CY1114792T1 (el) Κλωστριδιακες τοξινες για χρηση στην θεραπεια προωρης εκσπερματισης
BR112014031421A2 (pt) composições para tratamento de câncer e métodos para produção das mesmas
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
EA201491221A1 (ru) Новые молекулы, ингибирующие jnk, для лечения различных болезней
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
BR112014008819A2 (pt) métodos para o tratamento de síndrome de vazamento vascular e câncer
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
AR069806A1 (es) Uso de un componente neurotoxico del complejo de toxina botulinica creada por la bacteria clostridium botulinum para reducir o evitar efectos colaterales
EP4124346A3 (en) Compositions and methods for treating diseases
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
EA201500371A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
MX376183B (es) Composiciones para el tratamiento de rosacea.
BR112018012749A2 (pt) composições para higiene pessoal
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
EA201490637A1 (ru) Растительные стероиды и их применения
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ